Anti-IGF2BP1/IMP1 antibody [EPR18791]

• IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-IGF2BP1/IMP1 antibody [EPR18791] (AB184305)

Immunohistochemical analysis of paraffin-embedded human Hodgkin's lymphoma tissue labeling IGF2BP1/IMP1 with ab184305 at 1/4000 dilution, followed by Goat Anti-Rabbit IgG H&L (HRP) Ready to use. Sporadic cytoplasmic staining in human Hodgkin's lymphoma (PMID : 17296566) is observed. Counter stained with Hematoxylin.

Secondary antibody only control : Used PBS instead of primary antibody, secondary antibody is Goat Anti-Rabbit IgG H&L (HRP) Ready to use.

Heat mediated antigen retrieval was performed with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.

• IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-IGF2BP1/IMP1 antibody [EPR18791] (AB184305)

Immunohistochemical analysis of paraffin-embedded human lung cancer tissue labeling IGF2BP1/IMP1 with ab184305 at 1/4000 dilution, followed by Goat Anti-Rabbit IgG H&L (HRP) Ready to use. Cytoplasmic staining in human lung cancer (PMID : 17255263) is observed. Counter stained with Hematoxylin.

Secondary antibody only control : Used PBS instead of primary antibody, secondary antibody is Goat Anti-Rabbit IgG H&L (HRP) Ready to use.

Heat mediated antigen retrieval was performed with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.

• IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-IGF2BP1/IMP1 antibody [EPR18791] (AB184305)

Immunohistochemical analysis of paraffin-embedded human tonsil tissue labeling IGF2BP1/IMP1 with ab184305 at 1/4000 dilution, followed by Goat Anti-Rabbit IgG H&L (HRP) Ready to use. Cytoplasmic staining in germinal center of human tonsil (PMID : 17296566) is observed. Counter stained with Hematoxylin.

Secondary antibody only control : Used PBS instead of primary antibody, secondary antibody is Goat Anti-Rabbit IgG H&L (HRP) Ready to use.

Heat mediated antigen retrieval was performed with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.

• IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-IGF2BP1/IMP1 antibody [EPR18791] (AB184305)

Immunohistochemical analysis of paraffin-embedded human testis tissue labeling IGF2BP1/IMP1 with ab184305 at 1/4000 dilution, followed by Goat Anti-Rabbit IgG H&L (HRP) Ready to use. Cytoplasmic staining in human testis (PMID : 16049158) is observed. Counter stained with Hematoxylin.

Secondary antibody only control : Used PBS instead of primary antibody, secondary antibody is Goat Anti-Rabbit IgG H&L (HRP) Ready to use.

Heat mediated antigen retrieval was performed with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.

• IP

Unknown

Immunoprecipitation - Anti-IGF2BP1/IMP1 antibody [EPR18791] (AB184305)

IGF2BP1/IMP1 was immunoprecipitated from 0.35 mg of K562 (human chronic myelogenous leukemia cell line from bone marrow) whole cell lysate with ab184305 at 1/30 dilution. Western blot was performed from the immunoprecipitate using ab184305 at 1/1000 dilution. VeriBlot for IP Detection Reagent (HRP) (ab131366), was used for detection at 1/10,000 dilution.

Lane 1 : K562 whole cell lysate 10 μg (Input).
Lane 2 : ab184305 IP in K562 whole cell lysate.
Lane 3 : Rabbit monoclonal IgG (ab172730) instead of ab184305 in K562 whole cell lysate.

Exposure time : 1 second.

Blocking and dilution buffer and concentration : 5% NFDM/TBST.

Faint, lower molecular mass bands are observed in some human cell lines including K562. These could be an isoform (Isoform 2 predicted to be 48.5kDa) and degradation products, as described in the literature (PMID : 11641779).

All lanes:

Immunoprecipitation - Anti-IGF2BP1/IMP1 antibody [EPR18791] (ab184305)

Predicted band size: 63 kDa

Observed band size: 64 kDa

true

Exposure time: 1s

• WB

Supplier Data

Western blot - Anti-IGF2BP1/IMP1 antibody [EPR18791] (AB184305)

Exposure times : Lane 1 : 102 seconds; Lanes 2,3 : 3 minutes.

Blocking/Dilution buffer : 5% NFDM/TBST.

Faint, lower molecular mass bands are observed in some human cell lines including K562. These could be an isoform (Isoform 2 predicted to be 48.5kDa) and degradation products, as described in the literature (PMID : 11641779). The BxPC-3 and MCF7 cell lines are negative controls (PMID 26917013).

Lane 1:

Western blot - Anti-IGF2BP1/IMP1 antibody [EPR18791] (ab184305) at 1/10000 dilution

Lanes 2 - 3:

Western blot - Anti-IGF2BP1/IMP1 antibody [EPR18791] (ab184305) at 1/1000 dilution

Lane 1:

K562 (human chronic myelogenous leukemia cell line from bone marrow) whole cell lysate at 10 µg

Lane 2:

MCF7 (human breast adenocarcinoma cell line) whole cell lysate at 10 µg

Lane 3:

BxPC-3 (human pancreas adenocarcinoma cell line) whole cell lysate at 10 µg

Secondary

All lanes:

Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/100000 dilution

Predicted band size: 63 kDa

Observed band size: 64 kDa

true

• WB

Supplier Data

Western blot - Anti-IGF2BP1/IMP1 antibody [EPR18791] (AB184305)

Exposure times : Lane 1 : 8 seconds; Lanes 2,3 : 15 seconds; Lane 4 : 3 minutes.

Blocking/Dilution buffer : 5% NFDM/TBST.

Lane 1:

Western blot - Anti-IGF2BP1/IMP1 antibody [EPR18791] (ab184305) at 1/5000 dilution

Lanes 2 - 4:

Western blot - Anti-IGF2BP1/IMP1 antibody [EPR18791] (ab184305) at 1/1000 dilution

Lane 1:

HEK-293 (human epithelial cell line from embryonic kidney) whole cell lysate at 10 µg

Lane 2:

Human fetal liver tissue lysate at 10 µg

Lane 3:

HeLa (human epithelial cell line from cervix adenocarcinoma) whole cell lysate at 10 µg

Lane 4:

Human fetal kidney tissue lysate at 10 µg

Secondary

Lanes 1 - 3:

Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/100000 dilution

Lane 4:

Western blot - VeriBlot for IP Detection Reagent (HRP) (<a href='/en-us/products/reagents/veriblot-for-ip-detection-reagent-hrp-ab131366'>ab131366</a>) at 1/100000 dilution

Predicted band size: 63 kDa

Observed band size: 64 kDa

true

• WB

Supplier Data

Western blot - Anti-IGF2BP1/IMP1 antibody [EPR18791] (AB184305)

Blocking and diluting buffer : 5% NFDM/TBST.

This antibody shows weak cross reactivity with IGF2BP2.

ab205606 was used as a loading control at 1/1000 dilution.

ab179807 was used at 1/1000 dilution.

Lanes 1 - 3:

Western blot - Anti-IGF2BP1/IMP1 antibody [EPR18791] (ab184305) at 1/1000 dilution

Lanes 1 - 3:

Western blot - Anti-IMP3 antibody [EPR12021-114] (<a href='/en-us/products/primary-antibodies/imp3-antibody-epr12021-114-ab179807'>ab179807</a>) at 1/1000 dilution

Lane 1:

C-Myc/DDK-tagged full length Human IGF2BP1 recombinant at 0.01 µg

Lane 2:

C-Myc/DDK-tagged full length Human IGF2BP2 recombinant protein at 0.01 µg

Lane 3:

N-His-tagged full length Human IGF2BP3 recombinant protein at 0.01 µg

Secondary

All lanes:

Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/20000 dilution

Predicted band size: 63 kDa

Observed band size: 75 kDa

false

Exposure time: 180s

• WB

CiteAb

Western blot - Anti-IGF2BP1/IMP1 antibody [EPR18791] (AB184305)

IGF2BP1/IMP1 western blot using anti-IGF2BP1/IMP1 antibody [EPR18791] ab184305. Publication image and figure legend from Tang, L., Chen, Y., et al., 2020, J Cancer, PubMed 31897227.

ab184305 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab184305 please see the product overview.

DCST1-AS1 regulates the downstream proteins of miR-873-5p. (A) The expression level of IGF2BP1 in BRCA was analyzed by TCGA data. **, p < 0.0001. (B) TCGA data analysis showed that IGF2BP1 expressed higher levels in TNBC and luminal subtypes than normal controls, with significant differences. #, p < 0.05, *, p < 0.01. (C) The relationship between the expression of IGF2BP1 and the prognosis of BRCA patients was analyzed by TCGA data. P = 0.0054. (D) Western blot showed a decrease in the expression of IGF2BP1, MYC, LEF1 and CD44 in DCST1-AS1 interfering cells. (E) The miR-873-5p inhibitor was transfected into BT-549-si cells, and the expression of IGF2BP1 protein was measured by Western blot. (F) The miR-873-5p inhibitor was transfected into BT-549-si cells and cell proliferation was measured by CCK8 assay. *, p < 0.01. (G) The miR-873-5p inhibitor was transfected into BT-549-si cells and cell migration was measured by wound healing assay. *, p < 0.01.

false